Combination of iron chelator deferoxamine and ABCG2 transporter inhibitor lapatinib for therapeutic enhancement of 5‐aminolevulinic acid
Authors:
- 17 November 2025
- journal article
- Published by Wiley in Photochemistry and Photobiology
- Vol. 102 (3) , 666-675
Abstract
The use of 5‐aminolevulinic acid (ALA)‐induced protoporphyrin IX (PpIX) for tumor fluorescence imaging and photodynamic therapy (PDT) may be limited by intrinsic PpIX‐reducing mechanisms including PpIX bioconversion and efflux transport. The effectiveness of targeting these PpIX‐reducing mechanisms was evaluated in glioblastoma cell lines. Although either inhibiting PpIX bioconversion by an iron chelator deferoxamine (DFO) or suppressing PpIX efflux by an ABCG2 transporter inhibitor lapatinib (Lap) significantly increased ALA‐PpIX and PDT effect in the A172 cell line with weak ABCG2 activity, DFO in combination with Lap led to significantly greater enhancement effects. However, DFO did not significantly enhance ALA in H4, U‐87, and U‐118 cell lines with robust ABCG2 activities, whereas Lap showed effective enhancement effects. The combination of DFO and Lap enhanced ALA‐induced PpIX and PDT in these three cell lines. Not just increasing ALA‐PpIX levels, Lap enhanced PpIX localization in the mitochondria and promoted mitochondria‐mediated apoptosis after PDT in the H4 cell line with strong ABCG2 activities. Our results demonstrate that blocking ABCG2‐mediated PpIX efflux is critical for the enhancement of ALA and, in tumor cells with ABCG2 activities, inhibiting PpIX bioconversion by DFO needs to be combined with PpIX efflux suppression for effective enhancement of ALA.Keywords
Funding Information
- Foundation for the National Institutes of Health (R15CA268200)
This publication has 36 references indexed in Scilit:
- 5-Aminolevulinic acid-mediated photodynamic therapy in combination with kinase inhibitor lapatinib enhances glioblastoma cell deathApoptosis, 2024
- Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240)Journal of Neuro-Oncology, 2024
- Targeting ABCG2 transporter to enhance 5-aminolevulinic acid for tumor visualization and photodynamic therapyBiochemical Pharmacology, 2023
- Inhibition of ABCG2 transporter by lapatinib enhances 5-aminolevulinic acid-mediated protoporphyrin IX fluorescence and photodynamic therapy response in human glioma cell linesBiochemical Pharmacology, 2022
- Clinical uses of 5-aminolaevulinic acid in photodynamic treatment and photodetection of cancer: A reviewCancer Letters, 2020
- ABCG2 influence on the efficiency of photodynamic therapy in glioblastoma cellsJournal of Photochemistry and Photobiology B: Biology, 2020
- 5-ALA and FDA approval for glioma surgeryJournal of Neuro-Oncology, 2019
- Desferrioxamine shows different potentials for enhancing 5-aminolaevulinic acid-based photodynamic therapy in several cutaneous cell linesLasers in Medical Science, 2009
- Role of mitochondrial cardiolipin peroxidation in apoptotic photokilling of 5-aminolevulinate-treated tumor cellsArchives of Biochemistry and Biophysics, 2005
- Early apoptotic features of K562 cell death induced by 5-aminolaevulinic acid-based photodynamic therapyJournal of Photochemistry and Photobiology B: Biology, 2004